Glutathione S transferases polymorphisms are independent prognostic factors in lupus nephritis treated with cyclophosphamide

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Audemard Verger, Alexandra ^a   Silva, Nicolas Martin ^a   Verstuyft, Céline ^b   Costedoat Chalumeau, Nathalie ^c   Hummel, Aurélie ^d   Le Guern, Véronique ^c   Sacré, Karim ^e   Meyer, Olivier ^e   Daugas, Eric ^e   Goujard, Cécile ^b   Sultan, Audrey ^a   Lobbedez, Thierry ^a   Galicier, Lionel ^f   Pourrat, Jacques ^g   Le Hello, Claire ^a   Godin, Michel ^h   Morello, Rémy ^a   Lambert, Marc ⁱ   Hachulla, Eric ⁱ   Vanhille, Philippe ^j   Queffeulou, Guillaume ^k   Potier, Jacky ^k   Dion, Jean Jacques ^k   Bataille, Pierre ^k   Chauveau, Dominique ^g   Moulis, Guillaume ^g,l,m   Farge Bancel, Dominique ^f   Duhaut, Pierre ⁿ   Saint Marcoux, Bernadette ^o   Deroux, Alban ^p   Manuzak, Jennifer ^q   Francès, Camille ^r   Aumaitre, Olivier ^s   Bezanahary, Holy ^t   Becquemont, Laurent ^a   Bienvenu, Boris ^b   more..

^a CAEN UNIVERSITY HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e BICHAT HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER DE VALENCIENNES   (France)

^k CH Valenciennes ^*  (France)

^l Faculté de Médecine Centre Hospitalo universitaire   (France)

^m NS Park FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders   (France)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o Ho pital Aulnay sous bois   (France)

^p GRENOBLE UNIVERSITY HOSPITAL   (France)

^q INSTITUT COCHIN   (France)

^r HÔPITAL TENON   (France)

^s UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^t LIMOGES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; HYDROXYCHLOROQUINE; CREATININE; CYP2B6 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GSTP1 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CREATININE BLOOD LEVEL; CYP2B6 GENE; CYP2C19 GENE; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GST GENE; GSTM1 GENE; GSTP1 GENE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; ADVERSE DRUG REACTION; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETICS; LUPUS NEPHRITIS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; URINE; YOUNG ADULT;

ADULT; CREATININE; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C19; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINURIA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84962140563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151696     Document Type: Article

References (24)

1. Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. Autoimmun Rev. 2014; 13(11):1082-9. doi:10.1016/j.autrev.2014.08.034 PMID: 25172239.
2. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis and Rheum. 1995; 38(4):551-8.
3. Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: A study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus 1997; 6(3):248-53. PMID: 9104731.
4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine 2003; 82(5):299-308. PMID: 14530779.
5. Moroni G, Quaglini S, Galleli B, Banfi G, Messa P, Ponticelli C. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus 2013; 22(8):810-8. doi:10.1177/0961203313492576 PMID: 23764764.
6. Steinberg AD S Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991; 34(8):945-5058. PMID: 1859488.
7. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 26; 340(8822):741-5. PMID: 1356175.
8. Ekhart C, Doodeman VD, Rodenhuis S. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18(6):515-23. doi:10.1097/FPC.0b013e3282fc9766 PMID: 18496131.
9. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005; 44(11):1135-64. PMID: 16231966.
10. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 40-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999; 9:539-49 PMID: 10591534.
11. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006 Jan; 79103-13.
12. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11(5):399-415. PMID: 11470993.
13. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8:743-759. PMID: 17638512.
14. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994; 54 (23):6215-6220. PMID: 7954469.
15. Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L., Comets E et al. Low inter and intra individual variabilities in nevirapine pharma cokinetics in HIV-infected Cambodian patients (ANRS12154). Antimicrob Agents Chemother. 2010; 54(10):4432-9 doi:10.1128/AAC.00512-10 PMID: 20696882.
16. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000; 67(4):432-7. PMID: 10801254.
17. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and Rheum. 2004; 50(7):2202-10.
18. Singh G, Saxena N, Aggarwal A, Misra R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. The Journal of rheumatology 2007; 34(4):731-3. PMID: 17407229.
19. Winoto J, Song H, Hines C, Nagaraja H, Rovin BH. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy. Clin Nephrol. 2011; 75(5):451-7. PMID: 21543025.
20. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;10; 28(20):3227-33.
21. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol. 2006; 62(4):457-72. PMID: 16995867.
22. Vester U, Kranz B, Zimmermann S, Büscher R, Hoyer PF. The response to cyclophosphamide in steroid- sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases- M1 and -P1. Pediatr Nephrol. 2005; 20(4):478-81. PMID: 15717164.
23. Campbell JA, Corrigal AV, Guy A, Kirsch RE (1991). Immunohistologic localization of alpha, mu, and pi class glutathione S-transferases in human tissues. Cancer 67:1608-1613. PMID: 2001549.
24. Hadshiew I, Stäb F, Untiedt S, Bohnsack K, Rippke F, Hölzle E. Effects of topically applied antioxidants in experimentally provoked polymorphous light eruption. Dermatology. 1997; 195(4):362-8. PMID: 9529558.